Shihou Ito

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
  • Shihou Ito
  • Clinical pharmacology and therapeutics
  • 2015
Use of medicines in children is often off-label or off-evidence because essential information is lacking. Over the last two decades, consistent efforts have been made to render the regulatory framework more amenable to the needs of the pediatric population. Methodological progress is also evident. However, the consistent effort must be sustained.
  • Shihou Ito
  • Clinical pharmacology and therapeutics
  • 2011
a scrambled Rubik’s cube may not look like differentiated somatic cells, but solving the Rubik’s cube resembles the process of reprogramming somatic cells. The moment of transformation from a scrambled cube into its fully solved state is filled with a sense of excitement and accomplishment. Reprogramming of somatic cells into the stem cell state gives the(More)
  • Shihou Ito
  • Clinical pharmacology and therapeutics
  • 2017
The "Therapeutic Orphan" status of children is gradually improving, but our efforts to eliminate off-label/off-evidence use must be sustained for safer and more effective pediatric drug therapy. This is even more important in resource-scarce settings, because of the increasing child population in those regions. The juncture of pediatric pharmacology and(More)
The world's 1.89 billion children (age 0-14) too frequently receive treatments that have not been validated through clinical pharmacology research, especially in low- and middle-income countries. Initial findings from an international asset map of professionals and clinician scientists available to address the needs for education, research, and treatment(More)
This study assessed indicators of the need for insulin therapy and the effect of treatment on pregnancy outcomes in Japanese patients with gestational diabetes mellitus (GDM). All patients diagnosed with GDM were hospitalized for three days. Plasma glucose profiles in patients under strict dietary management and the characteristics of GDM patients with high(More)
  • Shihou Ito
  • Clinical pharmacology and therapeutics
  • 2014
The field of clinical pharmacology and therapeutics spans a wide spectrum of research areas involving human subjects at both individual and population levels. One of the key concepts relevant to all of these research areas is biotransformation of drug molecules, which can be defined as the chemical modification of drugs within an organism. This issue of the(More)
Internet-accessible computing power and data-sharing mandates now enable researchers to interrogate thousands of publicly available databases containing molecular, clinical, and epidemiological data. With emerging new approaches, translational bioinformatics can now provide answers to previously untouchable questions, ranging from detecting population(More)
  • Shihou Ito
  • Clinical pharmacology and therapeutics
  • 2016
Pregnancy and breastfeeding pose a unique challenge to drug development and clinical application. In addition to drug toxicity to the fetus in utero and infants through breastfeeding, alterations of pharmacokinetics in those women also need careful attention. How do we turn around the overall lack of drug efficacy and toxicity information for pregnant and(More)